SCHEMBL4984046

SCHEMBL4984046

O=C(CCSc1nc2ccccc2s1)Nc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.73
ALDH1A1 P00352 5/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
HPGD P15428 3/20 0.71
POLB P06746 1/20 0.71
TSHR P16473 1/20 0.71
MAPK1 P28482 1/20 0.71
HSD17B10 Q99714 1/20 0.71
LMNA P02545 5/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
CYP1A2 P05177 2/20 0.62
IDO1 P14902 1/20 0.62
CYP2C19 P33261 1/20 0.62
RAB9A P51151 2/20 0.62
NPC1 O15118 1/20 0.62
HTT P42858 1/20 0.62
RECQL P46063 1/20 0.62
ALOX5 P09917 1/20 0.60
CYP2D6 P10635 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144880 0.84 SMN1; SMN2 (1.00) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL29367809 0.84 SMN1; SMN2 (1.00) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL10645153 0.84 LMNA (0.59) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL6212355 0.83 MAPT (0.53) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL29229036 0.82 SMN1; SMN2 (0.97) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL10358385 0.82 SMN1; SMN2 (0.67) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL10644253 0.82 MAPT (0.57) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL10358601 0.81 MAPT (0.65) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL3497943 0.81 SMN1; SMN2 (0.84) MAPTALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL10358371 0.81 SMN1; SMN2 (0.66) MAPTALDH1A1SMN1; SMN2HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414066-B2 Amide compounds and medications containing the same technical field KOWA COMPANY LTD. (JP) 2008-08-19 US disclosed
US-7393866-B2 Amide compounds and medications containing the same KOWA COMPANY, LTD. (JP) 2008-07-01 US disclosed
EP-0979823-B1 NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2006-03-29 EP disclosed
EP-0807627-B1 Anilide compounds as ACAT inhibitors KOWA CO (JP) 2005-12-28 EP disclosed
US-20050131002-A1 Novel amide compounds and medications containing the same KOWA COMPANY LTD. (JP) 2005-06-16 US disclosed
US-20050131001-A1 Novel amide compounds and medications containing the same technical field KOWA COMPANY LTD. (JP) 2005-06-16 US disclosed
EP-1020451-B1 ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2005-06-15 EP disclosed
US-6849647-B1 Amide compounds and medications containing the same technical field KOWA COMPANY, LTD. (JP) 2005-02-01 US disclosed
US-6825223-B2 ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS; 2-SUBSTITUTED BENZIMIDAZOLE, BENZOXAZOLE, AND BENZOTHIAZOLES KOWA COMPANY, LTD. (JP) 2004-11-30 US disclosed
US-6797717-B2 ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS KOWA COMPANY, LTD. (JP) 2004-09-28 US disclosed
US-20030087928-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD., JAPAN 2003-05-08 US disclosed
US-20020099074-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD.,JAPAN 2002-07-25 US disclosed
US-20020037910-A1 Novel anilide compounds and pharmaceutical compositions comprising them SHIBUYA KIMIYUKI (JP) 2002-03-28 US disclosed
US-6362208-B1 ANTICHOLESTEROL AGENT KOWA COMPANY, LTD. (JP) 2002-03-26 US disclosed
US-6204278-B1 Anilide compounds, including use thereof in ACAT inhibitition KOWA COMPANY, LTD. (JP) 2001-03-20 US disclosed
EP-1020451-A1 NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME Kowa Co., Ltd. (JP) 2000-07-19 EP disclosed
EP-0979823-A1 NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME Kowa Company Ltd. (JP) 2000-02-16 EP disclosed
EP-0807627-A2 Anilide compounds as ACAT inhibitors Kowa Company Ltd. (JP) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131001-A1 Novel amide compounds and medications containing the same technical field ACAT2, SULT2A1, ACAT1 MAPT 1444/4885ALDH1A1 1256/4885SMN1; SMN2 2877/4885
US-20030087928-A1 Novel anilide compounds and drugs containing the same ACAT1, ACAT2, LCAT MAPT 400/4885ALDH1A1 211/4885SMN1; SMN2 4514/4885
US-20020037910-A1 Novel anilide compounds and pharmaceutical compositions comprising them ACAT1, LCAT, SOAT1 MAPT 775/4885ALDH1A1 356/4885SMN1; SMN2 3150/4885
US-20020099074-A1 Novel anilide compounds and drugs containing the same SOAT1, SOAT2, LCAT MAPT 1100/4885ALDH1A1 236/4885SMN1; SMN2 2945/4885
US-20050131002-A1 Novel amide compounds and medications containing the same ACAT2, SULT2A1, ACAT1 MAPT 930/4885ALDH1A1 1410/4885SMN1; SMN2 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.